Gemtuzumab Ozogamicin in the Treatment of Critical Patients with Refractory Acute Myeloid Leukemia (3 Case Reports)

DV Zaitsev, LL Girshova, VV Ivanov, IG Budaeva, DV Motorin, RSh Badaev, KV Bogdanov, YuV Mirolyubova, TS Nikulina, KA Zagorodnikova, NA Zhukova, SV Efremova, TV Chitanava, YuA Alekseeva, AY Zaritskey

VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341

For correspondence: Daniil Vladislavovich Zaitsev, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341; Tel.: +7(981)727-16-74; e-mail:

For citation: Zaitsev DV, Girshova LL, Ivanov VV, et al. Gemtuzumab Ozogamicin in the Treatment of Critical Patients with Refractory Acute Myeloid Leukemia (3 Case Reports). Clinical oncohematology. 2020;13(1):67–74 (In Russ).

DOI: 10.21320/2500-2139-2020-13-1-67-74


The treatment of refractory acute myeloid leukemia (AML) patients presents considerable challenges. They are often critically ill. The critical conditions of these patients are mainly associated with severe infectious complications resulting in sepsis as well as with the extramedullary lesions with organ dysfunctions. So far, the obtained data demonstrated the successful use of gemtuzumab ozogamicin, the mechanism of which is likely to be based not only on depletion of CD33-positive tumor cells but also on its immunomodulatory effect. The present article focuses on the fast-effect mechanisms of gemtuzumab ozogamicin and deals with clinical experience of successful use of this drug combined with hypomethylating agents in patients with refractory AML whose condition is critical by the time therapy begins. The use of this drug combination results in fast stabilization of health status, recovery of internal organs, and apyrexia with the decreasing systemic inflammatory response within the first days of therapy. All this together with significantly lower blast count in blood and in bone marrow can bring critically ill patients to recovery.

Keywords: acute myeloid leukemia, critically ill patients, gemtuzumab ozogamicin, refractory course.

Received: August 15, 2019

Accepted: December 16, 2019

Read in PDF


  1. Rabbat A, Chaoui D, Montani D, et al. Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol. 2005;129(3):350–7. doi: 10.1111/j.1365-2141.2005.05459.x.
  2. Thol F, Schlenk R, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3):319–27. doi: 10.1182/blood-2014-10-551911.
  3. Cardenas-Turanzas M, Ravandi-Kashani F, Cortes J, et al. Expectations of Serious Adverse Events at the End-of-Life of Patients with Acute Myeloid Leukemia Who Receive Salvage Therapy. Clin Lymph Myel Leuk. 2013;13(5):579–83. doi: 10.1016/j.clml.2013.03.021.
  4. Patil NK, Bohannon JK, Sherwood ER. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. Pharmacol Res. 2016;111:688–702. doi: 1016/j.phrs.2016.07.019.
  5. Demirkazik F, Akin A, Uzun O, et al. CT findings in immunocompromised patients with pulmonary infections. Diagn Intervent Radiol. 2008;14(4):75–82.
  6. Kovalski R, Hansen-Flaschen J, Lodato RF, Pietra GG. Localized leukemic pulmonary infiltrates. Diagnosis by bronchoscopy and resolution with therapy. Chest. 1990;97(3):674–8. dol: 1378/chest.97.3.674.
  7. Potenza L, Luppi M, Morselli M, et al. Leukaemic pulmonary infiltrates in adult acute myeloid leukaemia: a high-resolution computerized tomography study. Br J Haematol. 2003;120(6):1058–61. doi: 10.1046/j.1365-2141.2003.04192.x.
  8. Avni B, Koren-Michowitz M. Myeloid sarcoma: Current Approach and Therapeutic Options. Ther Adv Hematol. 2011;2(5):309–16. doi: 1177/2040620711410774.
  9. Lan T, Lin D, Tien H, et al. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol. 2009;122(4):238–46. doi: 1159/000253592.
  10. Byrd J, Weiss R, Arthur D, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15(2):466–75. doi: 10.1200/jco.1997.15.2.466.
  11. Ganzel C, Manola J, Douer D, et al. Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980–2008. J Clin Oncol. 2016;34(29):3544–53. doi: 10.1200/jco.2016.67.5892.
  12. Lengline E, Raffoux E, Lemiale V, et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leuk Lymphoma. 2012;53(7):1352–9. doi: 10.3109/10428194.2011.649752.
  13. Kurimoto M, Matsuoka H, Hanaoka N, et al. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. 2013;27(1):233–5. doi: 10.1038/leu.2012.178.
  14. Walter RB, Medeiros BC, Gardner KM, et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. 2014;99(1):54–9. doi: 10.3324/haematol.2013.096545.
  15. Medeiros BC, Tanaka TN, Balaian L, et al. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. Clin Lymph Myel Leuk. 2018;18(5):346–52. doi: 10.1016/j.clml.2018.02.017.
  16. McNeil MJ, Parisi MT, Hijiya N, et al. Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin. J Pediatr Hematol Oncol. 2019;41(3):e174–e176. doi: 10.1097/MPH.0000000000001201.
  17. Amadori S. New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin. Hematol Meet Rep. 2008;2(5):69–71.
  18. Takeshita A. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia. Int J Hematol. 2013;97(6):703–16. doi: 10.1007/s12185-013-1365-1.
  19. Aribi A, Kantarjian MH, Estey EH, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007;109(7):1355–9. doi: 10.1002/cncr.22524.
  20. Tsimberidou A-M, Estey E, Whitman GJ, et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res. 2004;28(9):991–4. doi: 1016/j.leukres.2004.01.004.
  21. Owonikoko T, Agha M, Balassanian R, et al. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol. 2007;4(8):491–5. doi: 10.1038/ncponc0899.
  22. Ando T, Mitani N, Matsunaga K, et al. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. J Exper Med. 2010;220(2):121–6. doi: 10.1620/tjem.220.121.
  23. Silverman LR, Fenaux P, Mufti GJ, et al. Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes. 2011;117(12):2697–702. doi: 10.1002/cncr.25774.
  24. Prokop A, Wrasidlo W, Lode H, et al. Induction of apoptosis by enediyne antibiotic calicheamicin θII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene. 2003;22(57):9107–20. doi: 10.1038/sj.onc.1207196.
  25. Wunderlich M, Stockman C, Devarajan M, et al. A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment. JCI Insight. 2016;1(15):e88181. doi: 10.1172/jci.insight.88181.
  26. Karakike E, Giamarellos-Bourboulis EJ. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front Immunol. 2019;10:55. doi: 10.3389/fimmu.2019.00055.
  27. Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood. 2017;130(6):699–712. doi: 10.1182/blood-2017-02-763086.
  28. Welch J, Petti A, Miller C, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023–36. doi: 1056/NEJMoa1605949.

  29. Stahl M, DeVeaux M, Montesinos P, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(8):923–32. doi: 10.1182/bloodadvances.2018016121.

  30. Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006;20(12):2093–101. doi: 10.1038/sj.leu.2404437.

  31. Nand S, Othus M, Godwin JE, et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. 2013;122(20):3432–3439. doi: 10.1182/blood-2013-06-506592.